Detection of MGMT promoter methylation in glioblastoma using pyrosequencing
- PMID: 25755756
- PMCID: PMC4348884
Detection of MGMT promoter methylation in glioblastoma using pyrosequencing
Abstract
Recent clinical trials on patients with glioblastoma revealed that O(6)-Methylguanine-DNA methyltransferase (MGMT) methylation status significantly predicts patient's response to alkylating agents. In this study, we sought to develop and validate a quantitative MGMT methylation assay using pyrosequencing on glioblastoma. We quantified promoter methylation of MGMT using pyrosequencing on paraffin-embedded fine needle aspiration biopsy tissues from 43 glioblastoma. Using a 10% cutoff, MGMT methylation was identified in 37% cases of glioblastoma and 0% of the non-neoplastic epileptic tissue. Methylation of any individual CpG island in MGMT promoter ranged between 33% and 95%, with a mean of 65%. By a serial dilution of genomic DNA of a homogenously methylated cancer cell line with an unmethylated cell line, the analytical sensitivity is at 5% for pyrosequencing to detect MGMT methylation. The minimal amount of genomic DNA required is 100 ng (approximately 3,000 cells) in small fine needle biopsy specimens. Compared with methylation-specific PCR, pyrosequencing is comparably sensitive, relatively specific, and also provides quantitative information for each CpG methylation.
Keywords: MGMT; epigenetics; glioblastoma; methylation; pyrosequencing.
Figures



Similar articles
-
Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1790-6. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973069 Free PMC article.
-
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.J Mol Diagn. 2007 Jul;9(3):368-81. doi: 10.2353/jmoldx.2007.060167. J Mol Diagn. 2007. PMID: 17591937 Free PMC article.
-
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.Acta Neuropathol. 2011 May;121(5):651-61. doi: 10.1007/s00401-011-0803-5. Epub 2011 Feb 3. Acta Neuropathol. 2011. PMID: 21287394
-
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.World J Surg Oncol. 2016 Oct 12;14(1):261. doi: 10.1186/s12957-016-1012-4. World J Surg Oncol. 2016. PMID: 27733166 Free PMC article. Review.
-
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.J Cell Physiol. 2018 Jan;233(1):378-386. doi: 10.1002/jcp.25896. Epub 2017 May 16. J Cell Physiol. 2018. PMID: 28266716 Review.
Cited by
-
The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.Dis Markers. 2015;2015:604719. doi: 10.1155/2015/604719. Epub 2015 Aug 11. Dis Markers. 2015. PMID: 26347581 Free PMC article.
-
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.J Neurooncol. 2016 Jun;128(2):333-9. doi: 10.1007/s11060-016-2116-y. Epub 2016 Mar 30. J Neurooncol. 2016. PMID: 27029617
-
Rapid Screen of Potential i-Motif Forming Sequences in DNA Repair Gene Promoters.ACS Omega. 2018 Aug 31;3(8):9630-9635. doi: 10.1021/acsomega.8b01551. Epub 2018 Aug 21. ACS Omega. 2018. PMID: 30198001 Free PMC article.
-
Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma.Iran J Pathol. 2019 Fall;14(4):290-298. doi: 10.30699/ijp.2019.94401.1922. Epub 2019 Sep 22. Iran J Pathol. 2019. PMID: 31754358 Free PMC article.
-
Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.Front Cell Dev Biol. 2021 Feb 5;9:600506. doi: 10.3389/fcell.2021.600506. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33614641 Free PMC article.
References
-
- Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507. - PubMed
-
- Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4. - PubMed
-
- Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Ré C. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010;97:311–22. - PubMed
-
- Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004;23:1–8. - PubMed
-
- Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaña C, Sanchez-Cespedes M, García-Villanueva M, Arribas L, Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials